Clostridium difficile.
George, a 55-year-old retired businessman with a diagnosis of myelofibrosis, underwent an allogeneic stem cell transplantation from his human leukocyte antigen-matched brother in June 2006. He was admitted to the hospital for a possible flare of graft-versus-host disease (GVHD) of the gut. His medications included tacrolimus, budesonide, and bechlamethasone for immunosuppression and pantoprazole. A stool sample was positive for Clostridium difficile toxin A on October 31, 2006, and he was started on oral metronidazole.
Hooker
Mallori
M
Rocky Mountain Cancer Center, Denver, CO, USA. mallori.hooker@usoncology.com
D000890:Anti-Infective Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000009:adverse effects; D001507:Beclomethasone / Q000009:adverse effects; D001706:Biopsy; D019819:Budesonide / Q000009:adverse effects; D016360:Clostridioides difficile / Q000502:physiology / Q000648:ultrastructure; D003113:Colonoscopy; D004761:Enterocolitis, Pseudomembranous / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D005243:Feces / Q000382:microbiology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D017053:Infection Control / Q000379:methods; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged; D009859:Oncology Nursing; D055728:Primary Myelofibrosis / Q000628:therapy; D012307:Risk Factors; D016559:Tacrolimus / Q000009:adverse effects; D014640:Vancomycin / Q000627:therapeutic use
D000890:Anti-Infective Agents; D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D008795:Metronidazole; D019819:Budesonide; D014640:Vancomycin; D001507:Beclomethasone; D016559:Tacrolimus